The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'.
Authors
Schöffski, PWozniak, A
Leahy, Michael G
Aamdal, S
Rutkowski, P
Bauer, S
Richter, S
Grünwald, V
Debiec-Rychter, M
Sciot, R
Geoerger, B
Marréaud, S
Collette, S
Nzokirantevye, A
Strauss, S
Affiliation
Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, LeuvenIssue Date
2018-05
Metadata
Show full item recordAbstract
Alveolar rhabdomyosarcomas (ARMSs) can harbour MET and anaplastic lymphoma kinase (ALK) alterations. We prospectively assessed crizotinib in patients with advanced/metastatic ARMS.Citation
The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 'CREATE'. 2018, 94: 156-167 Eur J CancerJournal
European Journal of CancerDOI
10.1016/j.ejca.2018.02.011PubMed ID
29567632Type
ArticleLanguage
enISSN
1879-0852ae974a485f413a2113503eed53cd6c53
10.1016/j.ejca.2018.02.011